{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'as backbones for treatment of HIV-1 infection in virologically suppressed adults: a', 'randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158-65.', 'GlaxoSmithKline (GSK) Document Number RM2007/00683/11: GSK1349572 Clinical', \"Investigator's Brochure Version 11. October 2017.\", 'GlaxoSmithKline Document Number 2017N352880 00: GSK1349572 Clinical', \"Investigator's Brochure, Version 11, Supplement 01, 11 December 2017.\", 'GlaxoSmithKline Document Number 2017N352880 ( 01: GSK1349572 Clinical', \"Investigator's Brochure, Version 11, Supplement 02, June 2018.\", 'GlaxoWellcome Document Number: GIO/94/005. A Randomized, Controlled', 'Lamivudine (3TC) Double-blind Trial to Compare the Safety and Efficacy of Zidovudine', '(ZDV) Monotherapy versus Lamivudine Plus ZDV in Combination in Treating HIV-1', 'Infected Patients Who Are ZDV Therapy with a CD4 Cell Counts between 100-400', 'cells/mm\u00b3 (Protocol No: NUCB3002). May 18, 1995.', 'GlaxoWellcome Document Number: UCR/95/003. A Randomized 3TC, ddC Double-', 'blind (ZDV Open-labeled) Multicenter Trial to Evaluate the Safety and Efficacy of 3TC', '(low dose) Administered Concurrently with Zidovudine (ZDV) Versus 3TC (high dose)', 'Administered Concurrently with ZDV Versus Dideoxycytidine (ddC) Administered', 'Concurrently with ZDV in the Treatment of HIV-1 Infected ZDV-experienced (~24', 'Weeks) Patients with CD4 Cell Counts of 100-300/mm\u00b3 (Protocol No: NUCA3002). May', '17, 1995.', 'Gunthard HF, Saag MS, Benson CA, et. al. Antiretroviral drugs for the treatment and', 'prevention of HIV infection in adults. 2016 recommendations of the International', 'Antiviral Society (IAS)-USA Panel. JAMA. 2016;316(2):191-210.', 'Hagins DP, Kumar PN, Saag M, et. al. Randomized switch to B/F/TAF in African', 'American adults with HIV. In: Program and abstracts of the 2020 Conference on', 'Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, Massachusetts.', 'Abstract 36.', 'Inker LA, Schmid CH, Tighiouart H, et al; Estimating Glomerular Filtration Rate from', 'Serum Creatinine and Cystatin C. N Engl J Med. 2012;367:20-9.', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduc in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Joly V, Burdet C, Landman R, et al. Promising results of dolutegravir + lamivudine', 'maintenance in ANRS 167 LAMIDOL trial. In: Program and abstracts of the 2017', 'Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle.', 'Abstract 458.', 'Justice A, Holmes W, Gifford A, et al. Development and validation of a self completed', 'HIV symptom index. Journal of Clinical Epidemiology. 2001; 54:S77-S90', '82']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human', 'immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential', 'factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013;207:1157-65.', 'Levey AS, Stevens LA, Schmid CH, et.al. A new equation to estimate glomerular', 'filtration rate. Ann Int Med. 2009;150:604-12.', 'Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: switch to DTG+RPV', 'maintains virologic suppression through 48 wks. In: Program and abstracts of the 2017', 'Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle.', 'Abstract 44LB.', 'Lui KJ, Kelly C. A revisit on tests for the homogeneity of the risk difference. Biometrics.', '2000;56:309-15.', 'Margolis DA, Brinson CC, Smith GH, et. al. Cabotegravir plus rilpivirine, once a day,', 'after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in', 'antiretroviral-na\u00efve adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-', 'ranging trial. Lancet Infect Dis. 2015 Oct; 5(10): 1145-55. doi: 0.1016/S1473-', '3099(15)00152-8.', 'Mills A, Arribas JR, Andrade-Villanueva J, et. al. Switching from tenofovir disoproxil', 'fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed', 'adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label,', 'phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43-52.', 'Molina JM, Ward D, Brar I, et al. Switching from fixed-dose bictegravir, emtricitabine,', 'and tenofovir alafenamide from dolutegravir plus abacavir plus lamivudine in', 'virologically suppressed adults with HIV-1: 48 week results of a randomised, double-', 'blind, multicenter, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018.', 'Palella FJ, Fisher M, Tebas P, et. al. Simplification to rilpivirine/emtricitabine/tenofovi', 'disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a', 'randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335-44.', 'Paterson D, Swindells S, Mohr J, et. al. How Much Adherence is Enough? A Prospective', 'Study of Adherence to Protease Inhibitor Therapy Using MEMSCaps. Abstract 92, 6th', 'Conference on Retrovirus and Opportunistic Infections. 1999; 84.', 'Perez-Molina. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple', 'treatment with atazanavir-ritonavir plus two nucleos(t)ides. Lancet Infect Dis.', '2015;15:775-84.', 'Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification', 'Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the', \"FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry.\", '2007;164:1035-43.', '83']\n\n###\n\n", "completion": "END"}